Suspension Culturing of Pluripotent Stem Cells

• US 20160215268A1
• Filed: 12/09/2015
• Published: 07/28/2016
• Est. Priority Date: 12/19/2014
• Status: Abandoned Application

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Inventors: Fryer, Benjamin, Laniauskas, Daina
• Application Number:
  US14/963,730
• Publication Number:
  US 20160215268A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: C12N 2500/02 Atmosphere, e.g. low oxygen conditions
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2500/60 Buffer, e.g. pH regulation, osmotic pressure
• CPC Class Codes: C12N 2501/117 Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2501/19 Growth and differentiation factors [GDF]
• CPC Class Codes: C12N 2501/385 of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
• CPC Class Codes: C12N 2501/395 Thyroid hormones
• CPC Class Codes: C12N 2501/41 Hedgehog proteins; Cyclopamine (inhibitor)
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2501/727 Kinases (EC 2.7.)
• CPC Class Codes: C12N 2501/91 Heparin
• CPC Class Codes: C12N 2501/999 Small molecules not provided for elsewhere
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

The present invention provides methods of differentiating pluripotent cells into beta cell using suspension clustering. The methods of the invention use control of one or more of pH, cell concentration, and retinoid concentration to generate a nearly homogenous population of PDX1/NKX6.1 co-expressing cells by suppressing precocious NGN3 expression and promoting NKX6.1 expression. Also, the nearly homogenous population of PDX1/NKX6.1 co-expressing cells may be further differentiated in vitro to form a population of pancreatic endocrine cells that co-express PDX1, NKX6.1, insulin and MAFA.

Claims

1. A method for differentiation human pluripotent cells, comprising the steps of:

differentiating foregut endoderm cells to pancreatic endoderm cells by culturing the foregut endoderm cells in a dynamic suspension culture at a pH of about 7.2 to about 7.0 for at least about 24 hours.

2. The method of claim 1, further comprising culturing the foregut endoderm cells in culture having a cell concentration of equal to or greater than about 1.5 million cells/mL.

3. The method of claim 1, further comprising culturing the foregut endoderm cells in culture having a cell concentration of greater than or equal to about 2.0 million cells/mL.

4. The method of claiml, wherein the pancreatic endoderm cells are substantially negative for the expression of PTF1A and NGN3.

5. The method of claim 4, further comprising enriching the pancreatic endoderm cells that are substantially negative for the expression of PTF1A and NGN3 to a population of pancreatic endoderm cells having greater than or equal to about 96% cells that are positive for co-expression of PDX1 and NKX6.1 and that are positive for expression of PTF1A.

6. The method of claim 4, further comprising differentiating the pancreatic endoderm cells that are substantially negative for the expression of PTF1A and NGN3 to pancreatic endocrine in the absence of a differentiation stage in which cells positive for PTF1A expression are produced.

7. A method for differentiation human pluripotent cells, comprising the steps of:

differentiating foregut endoderm cells to pancreatic endoderm cells by culturing the foregut endoderm cells in a dynamic suspension culture at a pH of about 7.2 to about 7.0 for at least about 24 hours, a cell concentration of equal to or greater than about 1.5 million cells/mL, and a retinoid concentration of about 0.5 to about 1.0 wherein the culturing is carried out in the absence of components to one or more of inhibit, block, activate or agonize TGF-beta signaling and BMP signaling and a sonic hedgehog signaling pathway inhibitor.